Lantern Pharma shareholders elect directors and approve stock option repricing
Lantern Pharma Shareholders Choose Directors and argue for reproduction of stock option
pharma
Carlyle Group plans to sell up to 10% stake in Piramal Pharma
Carlyle Group plans to sell up to 10% share in Piramal Pharma
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Transactions in Zealand’s Pharma and/or related securities by managerial liability and/or their close associated persons to dismiss persons
EPIX DEADLINE TUESDAY: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages ESSA Pharma Inc. Investors to Secure Counsel Before Important March 25 Deadline in Securities Class Action – EPIX
Epix Deadline Tuesday: Rosen, Global and Leading Law Firm, Promotes Essa Pharma Inc. Investors to provide tips in a significant date of March 25 in the Securities Class Action – EPIX
Faruqi & Faruqi Reminds ESSA Pharma Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 25, 2025 – EPIX
Faruqi & Faruqi mentions Essa Pharma Investors on the current class action lawsuit that has a leading plaintiff’s deadline on March 25, 2025 – EPIX
3 reasons Bernstein strategists are bullish on the EU pharma sector into 2025 By Investing.com
Investing.com – Bernstein analysts are optimistic about Europe’s pharmaceutical sector as it heads into 2025, despite concerns about policy changes and market resistance. The firm identified three main reasons for the positive outlook in this week’s note Solid growth prospects: Bernstein forecasts 8% EPS compound annual growth rate (CAGR) from 2025 to 2030, excluding Novo … Read more